ABBV: Immunology, oncology, and neuroscience pipelines advance with strong data and strategic investments
Immunology assets SKYRIZI and RINVOQ continue to outperform, with new indications and combination therapies driving growth. Oncology and neuroscience pipelines advance with differentiated assets, while disciplined capital allocation supports long-term expansion. Multiple phase III milestones and ne…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.